Expert Talk brings the thoughts, views, problems and solutions about a product or company by some of the brightest minds in Pharmaceutical industry. Pharmaceutical Expert Interview can be provided by technical expert in their work area. However, Pharmaceutical Exclusive interview gives us a glance on particular company/product and their latest innovations. This can be of questions and answers form. Expert Talk identifies the capabilities of an organization and also discusses various things.
Todays pharmaceutical environment has become increasingly complex with more specialty products like biologics injectable and clinical trial drugs being shipped than ever The industry standard for commercial packaging is 120 hours which is no longer always adequate Better temperature control and the..
In this interview Peter Soelkner of Vetter discusses drug delivery trends for biologics and in particular prefilled syringes He offers insight into the advantages and challenges of this system for biologics important issues to consider upfront and talks about two differing manufacturing technologies..
In this executive management interview Peter Soelkner of Vetter explains the companys strategy behind its increased APAC presence offers his insights on the position of the APAC region as compared to other world markets and discusses the advantages that can result when large pharma and smallemerging..
Cloud solutions offer immediate returns in improving operational performance and reducing costs Multiple approaches to cloud solutions will be needed to satisfy life science industry needs complicating the development of a coherent cloud strategy..
China from other competitors such as India Russia and Brazil is that there are many patients in China who can afford expensive products In fact just about all of the multinational pharmaceutical companies have inlicensing groups that are particularly focussed on oncology..
R S Gaud is a senior academician in Pharma Sciences since the last 30 years and is responsible for shaping the Pharmacy division at NMIMS University He also has worked as an advisor at All India Council Technical Education for five years He is also a member of CII National Committee of Drugs Pharma..
Indias growing respect and legal regulatory framework for IPR favourable economic policies resulting into attractive investment destination and availability of huge talent pool for sustaining and growing operations is making India an attractive destination for multinationals now..
Because RD productivity is a problem for pharma the partnering opportunities are basically seen in licensing and acquisitions..
In the Indian scenario teachers are overburdened and are involved in too many nonacademic activities resulting in poor research output There are only a handful of universities and institutions with a serious focus on research..
PPPs is being seen as an effective strategy to reduce pipeline stress and also keep the spiralling cost of drug discovery and development under control..